Stock listing

NASDAQ:VTGN Vistagen Therapeutics, Inc. Stock

Home listing (NASDAQ) of Vistagen Therapeutics, Inc.

Follow Vistagen Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:VTGN

$0.20 USD -0.01 (-6.1%)

Close on Oct 16, 2026

Since Jul 6, 2026 -20.0% · daily closes, Jul 6, 2026 – Oct 16, 2026, adjusted for splits
Day range
$0.198 – $0.219 USDOct 16, 2026
Volume
557,972 sharesOct 16, 2026
Market value
$8.88M USDAt the close on Oct 16, 2026 · price × 44.38M shares outstanding
Vistagen Therapeutics, Inc. logo
Ticker
NASDAQ:VTGN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • Vistagen Therapeutics (NASDAQ:VTGN) Q3 2026 Earnings Call

    Thu, Feb 12, 2026 · 5:00 PM ET

    Watch Transcript

  • Vistagen Therapeutics (NASDAQ:VTGN) Q2 2026 Earnings Call

    Thu, Nov 13, 2025 · 5:00 PM ET

    Watch Transcript

  • Vistagen Therapeutics (NASDAQ:VTGN) Q1 2026 Earnings Call

    Thu, Aug 07, 2025 · 5:00 PM ET

    Watch Transcript

Latest news

Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder

Sep 24, 2026

Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Sep 22, 2026

Vistagen to Present at Psych Congress 2026

Sep 10, 2026

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

Aug 14, 2026

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Aug 6, 2026

Vistagen Appoints Douglas J. Williamson to its Board of Directors

Jul 31, 2026

Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Jun 30, 2026

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Jun 15, 2026

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

Jun 9, 2026

Vistagen to Participate in Jefferies 2026 Global Healthcare Conference

May 27, 2026

All Vistagen Therapeutics, Inc. news

Decks

Vistagen Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
27 in the last 12 months · 148 in all · newest Sep 24, 2026 · oldest 2019
Calls
19 calls with a replay · 19 with a transcript · latest Feb 12, 2026
Decks
33 decks · latest September 2026

Where Vistagen Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:VTGN · Home listing · This pageNASDAQUnited StatesUSD
BOATS:VTGNBOATSUnited StatesUSD
BMV:VTGNBMVMexicoMXN
BIVA:VTGNBIVAMexicoMXN

Log in to ask 6ix AI your own questions about Vistagen Therapeutics, Inc.